MIRA INFORM REPORT

 

 

Report Date :

02.04.2012

 

IDENTIFICATION DETAILS

 

Name :

HILTON PHARMA (PRIVATE) LIMITED

 

 

Registered Office :

8th - 9th Floor, Progressive Plaza, Beaumont Road, Civil Lines Quarters, Near Dawood Centre, Karachi

 

 

Country :

Pakistan

 

 

Date of Incorporation :

1989

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products

 

 

No. of Employees :

202      

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Good

 

 

Payment Behaviour :

No complaints 

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Business Name

 

HILTON PHARMA (PRIVATE) LIMITED

 

 

Full Address       

 

Registered Address

8th - 9th Floor, Progressive Plaza, Beaumont Road, Civil Lines Quarters, Near Dawood Centre, Karachi, Pakistan

                                   

Tel #

92 (21) 35656500, 35656531

Fax #

92 (21) 35656417

Website

www.hiltonpharma.com

 

 

Short Description Of Business

 

a.

Nature of Business        

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

1989

c.

Registration #

0020789 (Old Registration No. was 1759/19891207)

 

 

 

 

 

Branches

 

Address

4th Floor, Nizam Chambers, Queens Road, Lahore, Pakistan

Tel #

92 (42) 36304403, 36304401

Fax #

92 (42) 36311189

 

 

Factory Location

 

Plot # 13, Sector 15,

Korangi Industrial Area, Karachi,

Pakistan

 

Auditors

 

M/s Mansoor Seraj Saleem & Co.

(Chartered Accountants)

B-1, Bycula Mansion, Shahrah-e-Liaquat, Karachi, Pakistan

 

Legal Status

 

Subject Company was incorporated as a Private Limited Company in 1989

 

Authorized Capital

Rs. 100,000,000/- divided into 10,000,000 shares of Rs. 10/- each

Issued & Paid up Capital

Rs. 15,000,000/- divided into 1,500,000 shares of Rs. 10/- each

 

 

Details of Directors

 

Names

Nationality

Address

Occupation

Designation

Mr. Shahbaz Yasin Malik

 

 

 

Mr. Shahid Yasin Malik

Pakistani

 

 

 

 

Pakistani

 

 

 

35, Khayaban-e-Jabal, Phase V, Defence Housing Authority, Karachi

 

35, Khayaban-e-Jabal, Phase V, Defence Housing Authority, Karachi

Business

 

 

 

 

Business

 

 

 

Chief Executive

 

 

 

 

Director

 

 

 

 

 

Shareholders                

 

Names

Number of Shares

Mr. Shahbaz Yasin Malik

 

Mr. Shahid Yasin Malik

750,000

 

750,000

 

 

Associated Companies

 

(1) N. Y. International (Private) Limited, Pakistan.

(2) Progressive Associates (Private) Limted, Pakistan.

(3) Progressive Medicals (Private) Limited, Pakistan.

(4) Progressive Systems (Private) Limited, Pakistan.        

 

 

Products

 

ALP, ANAPAZ, ARTEM, BETAGE, BLOPRESS, CARLOV, CEFIM, CELART, CEROPHENE, CITANEW, CRAVIT, ENFLOR, ESORID, FEROSOFT, FEROSOFT FA, FEROSOFT-S, FERTINORM, FEXO, FEXO-D, FLOXIN, FLUX, GEVOLOX, GEVOLOX-PLUS, GONAL F, HEPADIAL, HICLOR, HIFLOX, HITOP, LAEVOLAC, LEFORA, LEOZIN, LOXONIN, MAXIT, MAXIT-S, MEGADOX, METHYCOBAL, MIOMAX, MYONAL, MYTEKA, NEOGAB, OFLOBID, PILFOOD, PIOZER, PRALIP, PROFASI, QUSEL, RONEX, STIMOL, TIAZEM, TRANSAMIN, VALODIN, XOBIX, ZOPENT

 

 

Number of Employees

 

202      

 

 

Annual Production Volume

 

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture.

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2009

320,000,000/- (Estimated)

 

 

Trade Suppliers (Foreign)

 

(1)     ALPHARMA AS., NORWAY

(2)     LABORATORIES BIOCODEX, FRANCE.

(3)     DAIICHI PHARMACEUTICAL & CO LTD, JAPAN.

(4)     EISAI CO LTD, JAPAN.         

(5)     FRESENIUS KABI AUSTRIA GMBH, AUSTRIA.

(6)     CHINA KUNMING PHARMACEUTICAL CORP, CHINA.

(7)     MEIJI SEIKA KAISHA LTD, JAPAN.

(8)     PROBIOTICS INTERNATIONAL  LIMITED., U.K.

(9)     SANKYO CO., LTD., JAPAN.

(10) ARES SERONO INTERNATIONAL S.A., SWITZERLAND.

(11) TAKEDA CHEMICALS INDUSTRIES LTD., JAPAN.

(12) YAMANOUCHI PHARMACEUTICAL CO LTD., JAPAN.

 

 

Customers

 

Mainly Pharmacies, Distributors, Hospitals & Trading Companies etc

 

 

 

 

Exporting Countries

 

Mainly to South East Asia, Africa, Asia Pacific & Central Asian Republic Countries

 

 

Bankers

 

(1)     Habib Metropolitan Bank Limited, Pakistan.

      (Mortgage obtained PKR 67,000,000/-)

 

(2)     Bank Alfalah Limited, Pakistan.

 

(3)     Faysal Bank Limited, Pakistan.

 

(4)     Soneri Bank Limited, Pakistan.

 

(5) NIB Bank      Limited, Pakistan.

 

(6) Bank Alhabib Limited, Pakistan.

 

 

Memberships

 

·         Karachi Chamber of Commerce & Industry.(KCCI)

·         Pakistan Pharmaceutical Manufacturers Association.(PPMA)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 90.50

UK Pound

1

           Rs. 144.00

Euro

1

           Rs. 120.30

 

 

Comments

 

Subject Company was established in 1989 and is engaged in manufacture & marketing of Pharmaceutical Products. Directors are reported as resourceful, qualified and experienced businessmen. Trade relations are reported as fair.  Company can be considered for normal business dealings at usual trade terms and conditions.

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.51.15

UK Pound

1

Rs.81.79

Euro

1

Rs.68.34

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.